- Previous Close
3.3800 - Open
3.1500 - Bid 3.5200 x 300
- Ask 3.6800 x 200
- Day's Range
2.9300 - 3.7200 - 52 Week Range
1.8000 - 14.5950 - Volume
268,590 - Avg. Volume
238,180 - Market Cap (intraday)
158.997M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2100 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.08
TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer. It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December, 2023. TuHURA Biosciences, Inc. was incorporated in 1993 and is based in Tampa, Florida.TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc. .
tuhurabio.comRecent News: HURA
View MorePerformance Overview: HURA
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HURA
View MoreValuation Measures
Market Cap
146.33M
Enterprise Value
134.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.33M
Diluted EPS (ttm)
-1.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
19.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--